CN Patent

CN117860866A — 用于女性性功能障碍的布雷默浪丹疗法

Assigned to Koset Pharmaceutical Co · Expires 2024-04-12 · 2y expired

What this patent protects

本申请涉及用于女性性功能障碍的布雷默浪丹疗法。约1.0mg和1.75mg之间的皮下注射剂量的布雷默浪丹或布雷默浪丹的一种药学上可接受的盐用于在妇女中治疗女性性功能障碍同时降低或最小化不希望的副作用的用途。

USPTO Abstract

本申请涉及用于女性性功能障碍的布雷默浪丹疗法。约1.0mg和1.75mg之间的皮下注射剂量的布雷默浪丹或布雷默浪丹的一种药学上可接受的盐用于在妇女中治疗女性性功能障碍同时降低或最小化不希望的副作用的用途。

Drugs covered by this patent

bremelanotide-acetate (BREMELANOTIDE ACETATE)

Patent Metadata

Patent number: CN117860866A
Jurisdiction: CN
Classification: —
Expires: 2024-04-12
Drug substance claim: No
Drug product claim: No
Assignee: Koset Pharmaceutical Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.